1196732-52-1

Basic information

• Product Name: Propargyl-PEG8-amine
• Synonyms: Propargyl-PEG8-amine;HC≡C-CH2-PEG8-NH2;Propyne-PEG8-amine;Alkyne-PEG8-NH2
• CAS NO: 1196732-52-1
• Molecular Formula: C₁₉H₃₇NO₈
• Molecular Weight: 407.49898
• Mol File: 1196732-52-1.mol

Chemical Properties

• Appearance: /
• Solubility: Soluble in Water, DMSO, DCM, DMF
• CAS DataBase Reference: Propargyl-PEG8-amine(CAS DataBase Reference)
• NIST Chemistry Reference: Propargyl-PEG8-amine(1196732-52-1)
• EPA Substance Registry System: Propargyl-PEG8-amine(1196732-52-1)

Safety Data

• Hazardous Substances Data: 1196732-52-1(Hazardous Substances Data)

Usage

Uses

Used in Bioconjugation and Drug Synthesis:
Propargyl-PEG8-amine is utilized as a reactant in the synthesis of synthetic antibody mimics targeting prostate cancer. Its dual functional groups enable the formation of stable covalent bonds and triazole linkages, making it a versatile building block for the development of targeted therapeutic agents.
Used in Chemical Research and Development:
In the field of chemical research and development, Propargyl-PEG8-amine serves as a valuable intermediate for creating novel compounds and materials. Its ability to form amide bonds and participate in Click Chemistry reactions allows for the design of complex molecular structures with potential applications in various industries.
Used in Pharmaceutical Industry:
Propargyl-PEG8-amine is employed in the pharmaceutical industry as a key component in the synthesis of drug candidates and drug delivery systems. Its unique properties facilitate the development of innovative therapeutic agents with improved targeting, efficacy, and safety profiles.
Used in Diagnostic and Imaging Agents:
In the field of diagnostics and imaging, Propargyl-PEG8-amine is used to create contrast agents and probes for various imaging modalities. Its ability to form stable covalent bonds and triazole linkages enables the attachment of imaging moieties to targeting molecules, enhancing the diagnostic capabilities of imaging techniques.
Used in Material Science:
In material science, Propargyl-PEG8-amine is utilized in the development of functional materials with tailored properties. Its dual functional groups allow for the creation of materials with specific chemical and physical characteristics, such as self-healing properties, stimuli-responsive behavior, and improved mechanical strength.

Upstream product

• 352439-36-2 α-(2-azidoethyl)-ω-hydroxyhexa(oxyethylene) 
• 1351556-82-5 toluene-4-sulfonic acid 2-(2-{2-[2-(2-{2-[2-(2-prop-2-ynyloxyethoxy)ethoxy]ethoxy}ethoxy)ethoxy]ethoxy}ethoxy)ethyl ester 
• 1351556-81-4 2-(2-{2-[2-(2-{2-[2-(2-prop-2-ynyloxyethoxy)ethoxy]ethoxy}ethoxy)ethoxy]ethoxy}ethoxy)ethanol 
• 5117-19-1 octaethylene glycol 
• 1422540-96-2 C₂₇H₃₉NO₁₀ 
• 1422540-85-9 C₂₀H₃₈O₁₁S 
• 1196733-06-8 1-azido-3,6,9,12,15,18,21,24-octaoxaheptacos-26-yne 

Downstream Products

• 1196732-55-4 N-(2,4-dinitrophenyl)-3,6,9,12,15,18,21,24-octaoxaheptacos-26-yn-1-amine 
• 1196732-45-2 (S)-2-(3-((S)-1-carboxy-5-(4-(25-(2,4-dinitrophenylamino)-2,5,8,11,14,17,20,23-octaoxapentacosyl)-1H-1,2,3-triazol-1-yl)pentyl)ureido)pentanedioic acid 
• 1422541-07-8 C₄₆H₆₅N₃O₁₄S₂ 

Relevant articles and documents

Facial Synthesis and Bioevaluation of Well‐Defined OEGylated Betulinic Acid‐Cyclodextrin Conjugates for Inhibition of Influenza Infection

Betulinic acid (BA) and its derivatives exhibit a variety of biological activities, especially their anti‐HIV‐1 activity, but generally have only modest inhibitory potency against influenza virus. The entry of influenza virus into host cells can be competitively inhibited by multivalent derivatives targeting hemagglutinin. In this study, a series of hexa‐, hepta‐ and octavalent BA derivatives based on α-, β-and γ-cyclodextrin scaffolds, respectively, with varying lengths of flexible oligo(ethylene glycol) linkers was designed and synthesized using a microwave‐assisted copper‐catalyzed 1,3‐di-polar cycloaddition reaction. The generated BA‐cyclodextrin conjugates were tested for their in vitro activity against influenza A/WSN/33 (H1N1) virus and cytotoxicity. Among the tested com-pounds, 58, 80 and 82 showed slight cytotoxicity to Madin‐Darby canine kidney cells with viabilities ranging from 64 to 68% at a high concentration of 100 μM. Four conjugates 51 and 69–71 showed significant inhibitory effects on influenza infection with half maximal inhibitory concentration val-ues of 5.20, 9.82, 7.48 and 7.59 μM, respectively. The structure‐activity relationships of multivalent BA‐cyclodextrin conjugates were discussed, highlighting that multivalent BA derivatives may be potential antiviral agents against influenza infection.

TARGETED BIFUNCTIONAL DEGRADERS

The present invention provides, in one aspect, bifunctional compounds that can be used to promote or enhance degradation of certain circulating proteins. In another aspect, the present invention provides bifunctional compounds that can be used to promote or enhance degradation of certain autoantibodies. In certain embodiments, treatment or management of a disease and/or disorder requires degradation, removal, or reduction in concentration of the circulating protein or the autoantibody in the subject. Thus, in certain embodiments, administration of a compound of the invention to the subject removes or reduces the circulation concentration of the circulating protein or the autoantibody, thus treating, ameliorating, or preventing the disease and/or disorder. In certain embodiments, the circulating protein is TNF.

Comparative binding and uptake of liposomes decorated with mannose oligosaccharides by cells expressing the mannose receptor or DC-SIGN

Mannose Receptor (MR) and DC-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) are two mannose-specific targets for antigens carried by liposomes but DC-SIGN is more specific of DCs. Here, DC targeting is addressed by using DPPC/D

Efficient synthesis of diverse heterobifunctionalized clickable oligo(ethylene glycol) linkers: Potential applications in bioconjugation and targeted drug delivery

Herein we describe the sequential synthesis of a variety of azide-alkyne click chemistry-compatible heterobifunctional oligo(ethylene glycol) (OEG) linkers for bioconjugation chemistry applications. Synthesis of these bioorthogonal linkers was accomplished through desymmetrization of OEGs by conversion of one of the hydroxyl groups to either an alkyne or azido functionality. The remaining distal hydroxyl group on the OEGs was activated by either a 4-nitrophenyl carbonate or a mesylate (-OMs) group. The -OMs functional group served as a useful precursor to form a variety of heterobifunctionalized OEG linkers containing different highly reactive end groups, e.g., iodo, -NH2, -SH and maleimido, that were orthogonal to the alkyne or azido functional group. Also, the alkyne- and azide-terminated OEGs are useful for generating larger discrete poly(ethylene glycol) (PEG) linkers (e.g., PEG 16 and PEG24) by employing a Cu(i)-catalyzed 1,3-dipolar cycloaddition click reaction. The utility of these clickable heterobifunctional OEGs in bioconjugation chemistry was demonstrated by attachment of the integrin (αvβ3) receptor targeting peptide, cyclo-(Arg-Gly-Asp-d-Phe-Lys) (cRGfKD) and to the fluorescent probe sulfo-rhodamine B. The synthetic methodology presented herein is suitable for the large scale production of several novel heterobifunctionalized OEGs from readily available and inexpensive starting materials.

TLR-AGONIST-CONJUGATED ANTIBODY RECRUITING MOLECULES (TLR_ARMS)

The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) and Toll-like receptor agonist (TLR) through a linker and a multifunctional connector group or molecule.

CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS

The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an ant

Chemical control over immune recognition: A class of antibody-recruiting small molecules that target prostate cancer

(Figure Presented) Prostate cancer is the second leading cause of cancer-related death among the American male population, and society is in dire need of new approaches to treat this disease. Here we report the design, synthesis, and biological evaluation